FOREST LABORATORIES RECEIVES PATENT TERM EXTENSION FOR LEXAPRO

Forest Laboratories, Inc. announced today that a Notice of Final Determination was received from the U.S. Patent and Trademark Office by H. Lundbeck A/S, Forest's licensor, in connection with the patent term extension application for U. S. Patent No. Re. 34,712. The patent covers the composition of matter for Lexapro(R) (escitalopram oxalate) an SSRI approved for the treatment of Major Depressive Disorder and Generalized Anxiety Disorder in adults.
Finanzen.net